Kadmon Holdings, Inc. Class Action Lawsuit - KDMN

(i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the KDMN class action lawsuit, you must have incurred a loss on shares of Kadmon Holdings purchased during the class period listed above.

If you suffered a loss in Kadmon Holdings during the relevant time frame or pursuant to the relevant offering(s), you have until June 2, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.